Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer

Key facts

Sponsor

Sun Yat-sen University

Principal Investigator

Ming Kuang, PhD, M.D., Ph.D

First Affiliated Hospital, Sun Yat-Sen University

Intervention

Chemotherapy(drug)

Enrollment

92 enrolled

Eligibility

18-70 years · All sexes

Timeline

2020 – 2024

Study locations (1)

• The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Carcinoma of gallbladder and extrahepatic biliary tract

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT06901622
  Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
  The First Affiliated Hospital of Zhengzhou University
• RECRUITINGNCT07337850
  Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers
  Tata Memorial Centre
• RECRUITINGPHASE2NCT06440993
  Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
• ACTIVE NOT RECRUITINGPHASE2NCT05712356
  A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
  Lisata Therapeutics, Inc.
• ENROLLING BY INVITATIONPHASE3NCT06671418
  Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction
  Erasmus Medical Center
• RECRUITINGNCT05404347
  NGS in Gallbladder Cancer and Response to Treatment
  Banaras Hindu University

See all trials for Carcinoma of gallbladder and extrahepatic biliary tract →